Acarbose Reduces Diabetes Risk in Coronary Heart Disease
Incidence of new-onset diabetes was 18% lower in the acarbose group than in the placebo group during a median of 4.4 years of follow-up.
Grip strength has clinical utility in identifying people with diabetes at risk for poor health outcomes.
Mepsevii replaces beta-glucuronidase, the deficiency of which causes an abnormal buildup of toxic materials in the body's cells.
Investigators encourage further research on the use of NSAIDs in women with preeclampsia who develop postpartum hypertension.